Pediatric Hematology/Oncology and ImmunopathologyPediatric Hematology/Oncology and ImmunopathologyВопросы гематологии/онкологии и иммунопатологии в педиатрии1726-17082414-9314Fund Doctors, Innovations, Science for Children9910.24287/1726-1708-2015-14-2-12-19ЛИМФОМЫALK-positive anaplastic large cell lymphoma: Diagnosis, clinical manifestation, therapyALK-позитивная анапластическая крупноклеточная лимфома: диагностика, клинические проявления, лечениеAbramovD. S.АбрамовДмитрий Сергеевич
Russian Federation
pathmorf@mail.ruMyakovaN. V.МяковаНаталья Валерьевна
Russian Federation
nmiakova@mail.ruФедеральный научно-клинический центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева Минздрава России19052015142121919092018Copyright ©; 2015, «D. Rogachev NMRCPHOI»Copyright ©; 2015, ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России2015«D. Rogachev NMRCPHOI»ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава Россииhttps://creativecommons.org/licenses/by/4.0https://hemoncim.com/jour/article/view/99

I Anaplastic large cell lymphomas (ALCL), expressing anaplastic lymphoma kinase (ALK) - ALK-positive ALCL - form a group of malignant tumors of lymphoid origin, responsible for 10-15% of all non-Hodgkin's lymphomas in children. This review presents the morphological, phenotypical, cytogenetic, and clinical characteristics of ALK-positive ALCL and the significance of these characteristics for therapy.

Анапластические крупноклеточные лимфомы (АККЛ), экспрессирующие киназу анапластической лимфомы (anaplastic lymphoma kinase - ALK), - ALK-позитивные АККЛ - группа злокачественных опухолей лимфоидного происхождения, которые составляют 10-15% от всех неходжкинских лимфом у детей. В обзоре приведены морфологические, фенотипические, цитогенетические и клинические характеристики ALK-позитивной АККЛ, их значение для терапии.

детианапластическая крупноклеточная лимфомакиназа анапластической лимфомыдиагностикалечениеchildrenanaplastic large cell lymphomaanaplastic lymphoma kinasediagnosistherapyКриволапов ЮА, Леенман ЕЕ. Морфологическая диагностика лимфом. СПб.: Коста, 2006. / Krivolapov Yu A, Leenman EE. Morfologicheskaya diagnostika limfom. Saint Petersburg: Kosta, 2006. (In Russian).Greer JP, Kinney MC, Collins RD, Salhany KE, Wolff SN, Hainsworth JD, et al. Clinical features of 31 patients with Ki-1 anaplastic large-cell lymphoma. J Clin Oncol. 1991;9(4):539-47.Stein H, Masson DY, Gerdes J, O'Connor N, Wainscoat J, Pallesen G, et al. The expression of the Hodgkin’s disease associated antigen Ki-1 in reactive and neoplastic lymphoide tissue: evidence that Reed-Sternberg cells and hystocityc malignancies are derived from activated lymphoide cells. Blood. 1985;66(4):848-58.Stein H, Foss HD, Dürkop H, Marafioti T, Delsol G, Pulford K, et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood. 2000;96(12):3681-95.Lennert K, Feller AC. Histopathology of non-Hodgkin’s lymphomas: based on the update Kiel classification. Berlin: Springer-Verlag, 1992.Feller AC, Diebold J. Hystopathology of nodal and extranodal non-Hodgkin’s lymphomas: based on WHO classification. Berlin: Springer-Verlag, 2004.Chan JK, Ng CS, Hui PK, Leung TW, Lo ES, Lau WH, McGuire LJ. Anaplastic large cell Ki-1 lymphoma. Delineation of two morphological types. Histopathology. 1989;15(1):11-34.Schwab U, Stein H, Gerdes J, Lemke H, Kirchner H, Schaadt M, et al. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature. 1982:299(5878):65-7.Pileri S, Falini B, Delsol G, Stein H, Baglioni P, Poggi S, et al. Lymphohistiocytic T-cell lymphoma (anaplastic large cell lymphoma CD30+/Ki-1+ with a high content of reactive histiocytes). Histopathology. 1990;16(4):383-91.Kinney MC, Collins RD, Greer JP, Whitlock JA, Sioutos N, Kadin ME. A small-cell-predominant variant of primary Ki-1 (CD30)+ T-cell lymphoma. Am J Surg Pathol. 1993;17(9):859-68.Chan JK, Buchanan R, Fletcher CD. Sarcomatoid variant of anaplastic large cell Ki-1 lymphoma. Am J Surg Pathol. 1990;14(10):983-8.Mann KP, Hall B, Kamino H, Borowitz MJ, Ratech H. Neutrophil-rich, Ki-1-positive anaplastic large-cell malignant lymphoma. Am J Surg Pathol. 1995;19(4):407-16.Agnarsson BA, Kadin ME. Ki-1 positive large cell lymphoma: a morphologic and immunologic study of 19 cases. Am J Surg Pathol. 1988;12(4):264-74.Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri S, Stein H, et al., eds. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC, 2008:312-6.Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science. 1994;263(5151):1281-4.Gascoyne RD, Aoun P, Wu D, Chhanabhai M, Skinnider BF, Greiner TC, et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood. 1999;93(11):3913-21.Falini B, Martelli MP. Anaplastic large cell lymphoma: changes in the World Health Organization classification and perspectives for targeted therapy. Haematologica. 2009;94(7):897-900.Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer. 2008;8(1):11-23.Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, et al. ALK- anaplastic large cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specifide: report from the International Peripheral T-cell Lymphoma Project. Blood. 2008; 111(12):5496-504.Skinnider BF, Connors JM, Sutcliffe SB, Gascoyne RD. Anaplastic large cell lymphoma: a clinicopathologic analysis. Hematol Oncol. 1999;17(4):137-48.Armitage JO, Coiffier B, Dalla-Favera R, Harris NL, eds. Non-Hodgkin’s lymphomas. Philadelphia: Lippincott Williams & Wilkins, 2004.Hapgood G, Savage KJ. The biology and treatment of systemic anaplastic large cell lymphoma. Blood. 2015; pii: blood-2014-10-567461.Xing X, Feldman AL. Anaplastic large cell lymphomas: ALK positive, ALK negative and primary cutaneous. Adv Anat Pathol. 2015;22(1):29-49.Brugières L, Deley MC, Pacquement H, Meguerian-Bedoyan Z, Terrier-Lacombe MJ, Robert A, et al. CD30(+) anaplastic large-cell lymphoma in children: analysis of 82 patients enrolled in two consecutive studies of the French Society of Pediatric Oncology. Blood. 1998;92(10):3591-8.Seidemann K, Tiemann M, Schrappe M, Yakisan E, Simonitsch I, Janka-Schaub G, et al. Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large-cell lymphoma: a report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90. Blood. 2001 ;97(12) : 3699-706.Williams DM, Hobson R, Imeson J, Gerrard M, McCarthy K, Pinkerton CR. Anaplastic large cell lymphoma in childhood: analysis of 72 patients treated on The United Kingdom Children's Cancer Study Group chemotherapy regimens. Br J Haematol. 2002;117(4):812-20.Laver JH, Kraveka JM, Hutchison RE, Chang M, Kepner J, Schwenn M, et al. Advanced-stage large-cell lymphoma in children and adolescents: results of a randomized trial incorporating intermediate-dose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen: a Pediatric Oncology Group phase III trial. J Clin Oncol. 2005;23(3):541-7.Lowe EJ, Sposto R, Perkins SL, Gross TG, Finlay J, Zwick D, et al. Intensive chemotherapy for systemic anaplastic large cell lymphoma in children and adolescents: final results of Children's Cancer Group Study 5941. Pediatr Blood Cancer. 2009;52(3):335-9.Rosolen A, Pillon M, Garaventa A, Burnelli R, d'Amore ES, Giuliano M, et al. Anaplastic large cell lymphoma treated with a leukemia-like therapy: report of the Italian Association of Pediatric Hematology and Oncology (AIEOP) LNH-92 protocol. Cancer. 2005;104(10):2133-40.Brugières L, Le Deley MC, Rosolen A, Williams D, Horibe K, Wrobel G, et al. Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL Group. J Clin Oncol. 2009;27(6):897-903.Alessandri AJ, Pritchard SL, Schultz KR, Massing BG. A population-based study of pediatric anaplastic larg cell lymphoma. Cancer. 2002;94(6):1830-5.Le Deley MC, Rosolen A, Williams DM, Horibe K, Wrobel G, Attarbaschi A, et al. Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: results of the randomized ALCL99-vinblastine trial. J Clin Oncol. 2010;28(25):3987-93.Le Deley MC, Reiter A, Williams D, Delsol G, Oschlies I, McCarthy K, et al. Prognostic factors in childhoode anaplastic large cell lymphoma: results of a large European intergroup study. Blood. 2008;111(3):1560-6.Seropian S, Baheci E, Cooper DL. Allogeneic peripheral blood stem cell transplantation for high-risk non-Hodgkin's lymphoma. Bone Marrow Transplant. 2003;32(8):763-9.Boi M, Zucca E, Inghirami G, Bertoni F. Advances in understanding the pathogenesis of systemic anaplastic large cell lymphomas. Br J Haematol. 2015; 168(6):771-83.Furtado M, Rule S. Emerging pharmacotherapy for relapsed or refractory Hodgkin's lymphoma: focus on brentuximab vedotin. Clin Med Insights Oncol. 2012;6:31-9.Pro B, Anvani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic largecell lymphoma: results of a phase II study. J Clin Oncol. 2012;30(18):2190-6.Vaklavas C, Forero-Torres A. Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Ther Adv Hematol. 2012;3(4):209-25.Ansell SM. Brentuximab vedotin. Blood. 2014;124(22):3197-200.Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363(19):1812-21.Forero-Torres A, Leonard JP, Younes A, Rosenblatt JD, Brice P, Bartlett NL, et al. A phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol. 2009;146(2):171-9.Redaelli S, Farina F, Stasia A, Ceccon M, Mologni L, Messa C, et al. High response rates to crizotinib in advanced, chemoresistant ALK+ lymphoma patients. In: Abstract Book of the 55th ASH Annual Meeting. New Orleans, USA, 2013: abstr. 368.Gambacorti-Passerini C, Horibe K, Braiteh F, Huang H, Shi Y, Taylor M, et al. Safety and clinical activity of crizotinib in patients with ALK-rearranged hematologic malignancies. In: Abstract Book of the 55th ASH Annual Meeting. New Orleans, USA, 2013: abstr. 4342.Gambacorti-Passerini C, Messa C, Pogliani EM. Crizotinib in anaplastic large-cell lymphoma. N Engl J Med 2011;364(8):775-6.Nelson R. Crizotinib induces dramatic response in ALK-positive lymphoma. In: Abstract Book of the 52nd ASH Annual Meeting. Orlando, USA, 2010: abstr. 2877.